RT Journal Article
SR Electronic
T1 A SARS-CoV-2 serological assay to determine the presence of blocking antibodies that compete for human ACE2 binding
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.27.20114652
DO 10.1101/2020.05.27.20114652
A1 Byrnes, James R.
A1 Zhou, Xin X.
A1 Lui, Irene
A1 Elledge, Susanna K.
A1 Glasgow, Jeff E.
A1 Lim, Shion A.
A1 Loudermilk, Rita
A1 Chiu, Charles Y.
A1 Wilson, Michael R.
A1 Leung, Kevin K.
A1 Wells, James A.
YR 2020
UL http://medrxiv.org/content/early/2020/05/29/2020.05.27.20114652.abstract
AB As SARS-CoV-2 continues to spread around the world, there is an urgent need for new assay formats to characterize the humoral response to infection. Convalescent serum is being used for treatment and for isolation of patient-derived antibodies. However, currently there is not a simple means to estimate serum bulk neutralizing capability. Here we present an efficient competitive serological assay that can simultaneously determine an individual’s seropositivity against the SARS-CoV-2 Spike protein and estimate the neutralizing capacity of anti-Spike antibodies to block interaction with the human angiotensin converting enzyme 2 (ACE2) required for viral entry. In this ELISA-based assay, we present natively-folded viral Spike protein receptor binding domain (RBD)-containing antigens via avidin-biotin interactions. Sera are then supplemented with soluble ACE2-Fc to compete for RBD-binding serum antibodies, and antibody binding quantified. Comparison of signal from untreated serum and ACE2-Fc-treated serum reveals the presence of antibodies that compete with ACE2 for RBD binding, as evidenced by loss of signal with ACE2-Fc treatment. In our test cohort of nine convalescent SARS-CoV-2 patients, we found all patients had developed anti-RBD antibodies targeting the epitope responsible for ACE2 engagement. This assay provides a simple and high-throughput method to screen patient sera for potentially neutralizing anti-Spike antibodies to enable identification of candidate sera for therapeutic use.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJ.A.W. is grateful for funding from the Harry and Dianna Hind Endowed Professorship in Pharmaceutical Sciences and the Chan Zuckerberg Biohub that helped support this work. Postdoctoral Fellowship support included a National Health Institutes National Cancer Institute F32 (5F32CA239417 to J.R.B.), Damon Runyon Postdoctoral Fellowship (to X.X.Z.), and a Merck Postdoctoral Research Fellowship from the Helen Hay Whitney Foundation (to S.A.L.). The National Science Foundation Graduate Research Fellowship Program supported I.L. and S.K.E. Study enrollment and collection of patient and control sera were supported in part by National Institutes of Health grants R01-HL105704 (to C.Y.C.) from the National Heart, Lung, and Blood Institute, R33-129077 (to C.Y.C.) from the National Institute of Allergy and Infectious Diseases, and the Charles and Helen Schwab Foundation (to C.Y.C.). M.R.W. also thanks an endowment from the Rachleff Family for support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UCSF Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data presented are available upon request to the corresponding author.